NBW Capital LLC Grows Stake in Amgen Inc. (NASDAQ:AMGN)

NBW Capital LLC increased its holdings in Amgen Inc. (NASDAQ:AMGN) by 24.8% during the first quarter, HoldingsChannel reports. The institutional investor owned 1,066 shares of the medical research company’s stock after acquiring an additional 212 shares during the quarter. NBW Capital LLC’s holdings in Amgen were worth $303,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Capital International Investors increased its stake in Amgen by 547.8% in the first quarter. Capital International Investors now owns 7,005,269 shares of the medical research company’s stock valued at $1,991,738,000 after acquiring an additional 5,923,915 shares during the last quarter. Norges Bank purchased a new position in shares of Amgen in the 4th quarter worth about $1,556,912,000. Vanguard Group Inc. increased its position in shares of Amgen by 6.2% during the 1st quarter. Vanguard Group Inc. now owns 52,088,210 shares of the medical research company’s stock valued at $14,809,720,000 after purchasing an additional 3,045,657 shares during the last quarter. International Assets Investment Management LLC purchased a new position in shares of Amgen during the 4th quarter valued at about $4,589,900,000. Finally, Janus Henderson Group PLC lifted its position in Amgen by 137.1% in the 1st quarter. Janus Henderson Group PLC now owns 2,381,133 shares of the medical research company’s stock worth $676,984,000 after buying an additional 1,377,007 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Trading Down 0.5 %

Shares of NASDAQ:AMGN traded down $1.54 on Friday, hitting $333.99. The company had a trading volume of 2,106,216 shares, compared to its average volume of 1,890,833. The firm’s 50-day simple moving average is $316.30 and its two-hundred day simple moving average is $298.30. The firm has a market capitalization of $179.16 billion, a price-to-earnings ratio of 47.71, a P/E/G ratio of 2.78 and a beta of 0.58. The company has a quick ratio of 0.98, a current ratio of 1.42 and a debt-to-equity ratio of 11.96. Amgen Inc. has a 1 year low of $228.21 and a 1 year high of $346.85.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.76 by $0.20. The company had revenue of $7.45 billion during the quarter, compared to the consensus estimate of $7.45 billion. Amgen had a net margin of 12.74% and a return on equity of 156.21%. Amgen’s revenue was up 22.0% on a year-over-year basis. During the same period in the prior year, the firm earned $3.98 earnings per share. Equities analysts anticipate that Amgen Inc. will post 19.5 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, August 6th. Stockholders of record on Friday, August 16th will be paid a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.69%. Amgen’s payout ratio is presently 128.57%.

Analysts Set New Price Targets

AMGN has been the topic of several research reports. BMO Capital Markets lifted their price target on shares of Amgen from $336.00 to $355.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. Mizuho boosted their price target on shares of Amgen from $223.00 to $235.00 and gave the stock a “neutral” rating in a research note on Thursday, May 9th. StockNews.com upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. Argus lifted their price objective on Amgen from $300.00 to $340.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Finally, Morgan Stanley dropped their target price on Amgen from $310.00 to $303.00 and set an “equal weight” rating for the company in a report on Thursday, July 11th. Ten investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, Amgen currently has an average rating of “Moderate Buy” and a consensus target price of $312.63.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.